Servier: Precision Approach To Immunotherapy Will Define New Oncology Era
Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.
You may also be interested in...
The UK firm’s obe-cel has met the primary endpoint in a Phase II acute lymphocytic leukemia trial, triggering filing plans and a $150m public offering as observers commend the drug’s competitive safety profile.
Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.
Gilead claims that the mechanism used to work out the cost for the National Health Service in England of delivering CAR-T therapies to patients could threaten access to these medicines.